Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

In this study (n=453), the addition of pembrolizumab to etoposide and platinum (EP) chemotherapy was associated with improved progression-free survival (12-month estimates of 13.6% v 3.1% with placebo plus EP; HR 0.75; 95% CI 0.61 to 0.91; P=0.0023) but not overall survival.

Journal of Clinical Oncology